Patents by Inventor Alexandre Passioukov

Alexandre Passioukov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
    Patent number: 9360481
    Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: June 7, 2016
    Assignee: Roche Glycart AG
    Inventors: Lilla Di Scala, Stefan Evers, Christian Gerdes, Christoph Mancao, Alexandre Passioukov, Pablo Umana
  • Predictive biomarker for cancer treatment with ADCC-enhanced antibodies
    Publication number: 20140227256
    Abstract: The present invention is directed to methods for identifying which patients diagnosed with cancer will most benefit from treatment with an anti-cancer therapy comprising an ADCC-enhanced antibody.
    Type: Application
    Filed: January 21, 2014
    Publication date: August 14, 2014
    Applicant: ROCHE GLYCART AG
    Inventors: Lilla Di Scala, Stefan Evers, Christian Gerdes, Christoph Mancao, Alexandre Passioukov, Pablo Umana
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Patent number: 7893023
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: June 11, 2008
    Date of Patent: February 22, 2011
    Assignee: Medarex, Inc.
    Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Publication number: 20090076176
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Application
    Filed: June 11, 2008
    Publication date: March 19, 2009
    Applicant: MEDAREX, INC.
    Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Patent number: 7402556
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: July 22, 2008
    Assignee: Medarex, Inc.
    Inventors: André Trouet, Vincent Dubois, Alexandre Passioukov
  • Prodrugs activated by plasmin and their use in cancer chemotherapy
    Publication number: 20040171562
    Abstract: The product of the invention is a modified form of a therapeutic agent and comprises a therapeutic agent, an oligopeptide having a plasmin peptide substrate of 2-4 amino acids and mono- or di-peptide linkage, a stabilizing group and, optionally, a linker group. The prodrug is cleavable by plasmin. Also disclosed are methods of making and using the prodrug compounds.
    Type: Application
    Filed: October 31, 2003
    Publication date: September 2, 2004
    Inventors: Andre Trouet, Vincent Dubois, Alexandre Passioukov